Last update 21 Nov 2024
HA121-28
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms + [1] |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors), VEGFR antagonists(Vascular endothelial growth factor receptor antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Login to view timeline
Related
10
Clinical Trials associated with HA121-28HA121-28片治疗RET融合阳性晚期非小细胞肺癌的单臂、多中心、开放性 II 期临床研究
[Translation] A single-arm, multicenter, open-label phase II clinical study of HA121-28 tablets in the treatment of RET fusion-positive advanced non-small cell lung cancer
A Single-Arm, Multi-Centre, Open-Label Phase II Study of HA121-28 in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer
评价健康受试者口服HA121-28制剂B的相对生物利用度及食物对HA121-28制剂B药代动力学影响的Ⅰ期临床试验
[Translation] Phase I clinical trial to evaluate the relative bioavailability of HA121-28 formulation B and the effect of food on the pharmacokinetics of HA121-28 formulation B in healthy subjects
100 Clinical Results associated with HA121-28
Login to view more data
100 Translational Medicine associated with HA121-28
Login to view more data
100 Patents (Medical) associated with HA121-28
Login to view more data
100 Deals associated with HA121-28
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| RET fusion-positive Non-Small Cell Lung Cancer | Phase 2 | CN | 10 Mar 2022 | |
| Advanced Thyroid Gland Medullary Carcinoma | Phase 2 | CN | 13 Jul 2021 | |
| Thyroid Cancer, Medullary | Phase 2 | CN | 13 Jul 2021 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | CN | 19 Oct 2018 | |
| Esophageal Carcinoma | Preclinical | CN | 29 Mar 2017 | |
| Advanced Bile Duct Carcinoma | Discovery | CN | 22 Jun 2021 | |
| Biliary Tract Neoplasms | Discovery | CN | 27 May 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT03994484 (ESMO2021) Manual  | Phase 1 | 41 | (dose-escalation part) | (xtmwcoeqfg) = wo dose-limiting toxicities (grade-3 anorexia; prolonged QTc interval) occurred at 800 mg fycunssnmx (eqwynhbwub ) View more | Positive | 16 Sep 2021 | |
(dose-expansion part) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free